These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

588 related articles for article (PubMed ID: 30740921)

  • 1. Long-term outcomes of switching to aflibercept for treatment-resistant neovascular age-related macular degeneration.
    Spooner K; Hong T; Nair R; Chow NCC; Broadhead GK; Wijeyakumar W; Chang AA
    Acta Ophthalmol; 2019 Aug; 97(5):e706-e712. PubMed ID: 30740921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.
    Park DH; Sun HJ; Lee SJ
    Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocol.
    Jørstad ØK; Faber RT; Moe MC
    Acta Ophthalmol; 2017 Aug; 95(5):460-463. PubMed ID: 28556485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal ranibizumab versus aflibercept following treat and extend protocol for neovascular age-related macular degeneration.
    Abdin AD; Suffo S; Asi F; Langenbucher A; Seitz B
    Graefes Arch Clin Exp Ophthalmol; 2019 Aug; 257(8):1671-1677. PubMed ID: 31144055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of outer retinal tubulations in eyes switched from intravitreal ranibizumab to aflibercept for treatment of exudative age-related macular degeneration.
    Massamba N; Dirani A; Butel N; Fardeau C; Bodaghi B; Ingram A; Lehoang P
    Graefes Arch Clin Exp Ophthalmol; 2017 Jan; 255(1):61-67. PubMed ID: 27397583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept.
    Tyagi P; Juma Z; Hor YK; Scott NW; Ionean A; Santiago C
    BMC Ophthalmol; 2018 Jun; 18(1):148. PubMed ID: 29929478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of anti-VEGF therapies on fibrovascular pigment epithelial detachments in age-related macular degeneration.
    Au A; Parikh VS; Singh RP; Ehlers JP; Yuan A; Rachitskaya AV; Sears JE; Srivastava SK; Kaiser PK; Schachat AP; Martin DF; Modi Y
    Br J Ophthalmol; 2017 Jul; 101(7):970-975. PubMed ID: 27913442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD.
    Waizel M; Todorova MG; Masyk M; Wolf K; Rickmann A; Helaiwa K; Blanke BR; Szurman P
    BMC Ophthalmol; 2017 May; 17(1):79. PubMed ID: 28535756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.
    Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Ng P; Pecheur FL; McAllister IL
    JAMA Ophthalmol; 2019 Apr; 137(4):372-379. PubMed ID: 30676617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vision-related quality of life: 12-month aflibercept treatment in patients with treatment-resistant neovascular age-related macular degeneration.
    Zhu M; Wijeyakumar W; Syed AR; Joachim N; Hong T; Broadhead GK; Li H; Luo K; Chang A
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):475-484. PubMed ID: 27572301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indocyanine green angiography findings in patients with neovascular age-related macular degeneration refractory to ranibizumab switched to aflibercept.
    Calvo-Gonzalez C; Reche-Frutos J; Fernández-Vigo JI; Donate-López J; Serrano-García I; Fernández-Pérez C
    Int Ophthalmol; 2019 Nov; 39(11):2441-2448. PubMed ID: 30767090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of Treatment-Resistant Neovascular Age-Related Macular Degeneration Switched from Aflibercept to Faricimab.
    Raimondi R; Falfeli T; Bogdanova-Bennet A; Varma D; Habib M; Kotagiri A; Steel DH; Grinton M
    Ophthalmol Retina; 2024 Jun; 8(6):537-544. PubMed ID: 38040055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AFLIBERCEPT AFTER RANIBIZUMAB INTRAVITREAL INJECTIONS IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION: The ARI2 Study.
    Blanco-Garavito R; Jung C; Uzzan J; Quaranta-ElMaftouhi M; Coscas F; Sahel J; Korobelnik JF; Béchet S; Querques G; Souied EH
    Retina; 2018 Dec; 38(12):2285-2292. PubMed ID: 29190241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching to aflibercept versus continuing bevacizumab for treatment-resistant neovascular age-related macular degeneration: a one-year comparative observational study.
    Husum YS; Moe MC; Bragadóttir R; Jørstad ØK
    Acta Ophthalmol; 2021 Dec; 99(8):e1354-e1359. PubMed ID: 33638291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration.
    Marquis LM; Mantel I
    Graefes Arch Clin Exp Ophthalmol; 2020 Aug; 258(8):1591-1596. PubMed ID: 32399582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-Year Outcomes of Treat-and-Extend Intravitreal Aflibercept for Exudative Age-Related Macular Degeneration: A Prospective Study.
    Maruko I; Ogasawara M; Yamamoto A; Itagaki K; Hasegawa T; Arakawa H; Nakayama M; Koizumi H; Okada AA; Sekiryu T; Iida T
    Ophthalmol Retina; 2020 Aug; 4(8):767-776. PubMed ID: 32417356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-frequency aflibercept injections in persistent neovascular age-related macular degeneration.
    Muftuoglu IK; Tsai FF; Gaber R; Alam M; Meshi A; Freeman WR
    Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):709-717. PubMed ID: 27878592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One-year outcome of intravitreal ziv-aflibercept therapy for non-responsive neovascular age-related macular degeneration.
    Braimah IZ; Agarwal K; Mansour A; Chhablani J;
    Br J Ophthalmol; 2018 Jan; 102(1):91-96. PubMed ID: 28596286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Short-Term Choroidal Thickness and Retinal Morphological Changes after Intravitreal Anti-VEGF Therapy with Ranibizumab or Aflibercept in Treatment-Naive Eyes.
    Gharbiya M; Giustolisi R; Marchiori J; Bruscolini A; Mallone F; Fameli V; Nebbioso M; Abdolrahimzadeh S
    Curr Eye Res; 2018 Mar; 43(3):391-396. PubMed ID: 29166140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes by Baseline Choroidal Neovascularization Features in Age-Related Macular Degeneration: A Post Hoc Analysis of the VIEW Studies.
    Steinle NC; Du W; Gibson A; Saroj N
    Ophthalmol Retina; 2021 Feb; 5(2):141-150. PubMed ID: 32652314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.